Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice

Behavioural Pharmacology

Volumn 16, Issue 2, 2005, Pages 79-84

  De Oliveira, R V ^a   Dall'Igna, O P ^a   Tort, A B L ^a   Schuh, J F ^a   Neto, P F ^a   Gomes, M W Santos ^a   Souza, D O ^a   Lara, Diogo R ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Adenosine; Caffeine; Locomotion; MK 801; Mouse; NMDA; Schizophrenia; Tolerance

Indexed keywords

ADENOSINE; AMPHETAMINE; CAFFEINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ATAXIA; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; LOCOMOTION; LONG TERM MEMORY; MAZE TEST; MOUSE; NONHUMAN; SCHIZOPHRENIA; TASK PERFORMANCE; WORKING MEMORY;

ADENOSINE; AMPHETAMINE; ANIMALS; ATAXIA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LOCOMOTION; MALE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 16444379227     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200503000-00002     Document Type: Article

References (26)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 14:5545-5554.
2. Angelucci ME, Vital MA, Cesario C, Zadusky CR, Rosalen PL, Da Cunha C (1999). The effect of caffeine in animal models of learning and memory. Ear J Pharmacol 2-3:135-140.
3. Browne RG, Welch WM (1982). Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science 217:1157-1159.
4. Craig CG, White TD (1992). Low-level N-methyl-D-aspartate receptor activation provides a purinergic inhibitory threshold against further N-methyl-D-aspartate-mediated neurotransmission in the cortex. J Pharmacol Exp Ther 3:1278-1284.
5. Craig CG, White TD (1993). N-methyl-D-aspartate- and non-N-methyl-D- aspartate-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem 60:1073-1080.
6. Dall'Igna OP, Da Silva AL, Dietrich MO, Hoffmann A, de Oliveira RV, Souza DO, Lara DR (2003). Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice. Psychopharmacology (Berl) 166:258-263.
7. Delaney SM, Geiger JD (1998). Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J Pharmacol Exp Ther 285:568-572.
8. Finn IB, Holtzman SG (1987). Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity. Psychopharmacology (Berl) 93:428-434.
9. Fraser CM, Fisher A, Cooke MJ, Thompson ID, Stone TW (1997). Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology (Berl) 130:334-342.
10. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133.
11. Gimenez-Llort L, Martinez E, Ferre S (1995). Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-D-aspartate on motor activity in mice. Eur J Pharmacol 275:171-177.
12. Harvey J, Lacey MG (1997). A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 14:5271-5280.
13. + and glutamate. Brain Res 478:149-151.
14. Holtzman SG, Finn IB (1988). Tolerance to behavioral effects of caffeine in rats. Pharmacol Biochem Behav 29:411-418.
15. Honack D, Löscher W (1995). Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36:763-771.
16. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB (1996). Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108-113.
17. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28:1281-1291.
18. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. (1999). Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193-204.
19. Manzoni OJ, Manabe T, Nicoll RA (1994). Release of adenosine by activation of NMDA receptors in the hippocampus. Science 265:2098-2101.
20. Melani A, Corsi C, Gimenez-Llort L, Martinez E, Ogren SO, Pedata F, et al. (1999). Effect of N-methyl-D-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. Eur J Pharmacol 385:15-19.
21. 2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur J Pharmacol 333:143-146
22. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR (2002). Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22:6321-6324.
23. Sukhotina IA, Zvartau EE, Danysz W, Bespalov AY (2004). Caffeine withdrawal syndrome in social interaction test in mice: effects of the NMDA receptor channel blockers, memantine and neramexane. Behav Pharmacol 15:207-214.
24. Svenningsson P, Nomikos GG, Fredholm BB (1999). The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J Neurosci 19:4011-4022.
25. Uchihashi Y, Kuribara H, Tadokoro S (1992). Assessment of the ambulation-increasing effect of ketamine by coadministration with central-acting drugs in mice. Jpn J Pharmacol 60:25-31.
26. Von Lubitz DK, Paul IA, Carter M, Jacobson KA (1993). Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol 249:265-270.